Status:
RECRUITING
Metabolic Profiling of Esketamine Treatment in Depressive Disorder
Lead Sponsor:
University of Zagreb
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-70 years
Brief Summary
Major depressive disorder (MDD) is one of the most common psychiatric disorders, characterized by extremely high prevalence, relapse rate and therapeutic resistance. Treatment with ketamine and its en...
Eligibility Criteria
Inclusion
- for healthy control participants: 18-70 years, both sexes, without psychiatric drugs
- for patients: from 18- 70 years, both sexes, failed treatment attempts with at least two antidepressants of the appropriate dose and duration.
Exclusion
- for patients: treatment with tryptophan, St. John's wort, and/or opioid analgesics in the last month, daily intake of benzodiazepines;
- for all participants: presence of psychotic symptoms, alcohol and/or drug addiction, disorder seizures, eating disorder, dementia and other neurodegenerative diseases, epilepsy, intellectual disabilities, severe somatic diseases (including insufficiently controlled arterial hypertension, diabetes and thyroid diseases), active psychotherapeutic treatment (except supportive psychotherapy, which is an integral part of every psychiatric treatment and will be the same in all groups of respondents).
- Participants will be excluded if they follow a weight loss diet or take weight loss medication, are pregnant or breastfeeding.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07002684
Start Date
April 1 2023
End Date
December 31 2025
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tea Fabijanić
Zagreb, Croatia